Medivir acquires preclinical antiviral programs including hepatitis C and prodrug technologies

Stockholm, Sweden—Medivir AB (OMX: MVIR), announced today that it has acquired
preclinical research stage assets from Novadex Pharmaceuticals AB. The
acquisition includes intellectual property and prodrug technologies in order to
further strengthen Medivir’s hepatitis C platform and know how.

The acquired portfolio of research stage antiviral programs includes novel
nucleotide polymerase inhibitors that have been identified and developed. It
also includes prodrug technologies which could be applied to both protease
inhibitors and nucleoside analogues to enhance their overall pharmacokinetic
properties.

“We are very pleased to be able to make these additions to the Medivir R&D
portfolio, which will further strengthen our pipeline and capabilities in the
antiviral disease area. There are several synergies with the Medivir anti-viral
projects and prodrug approaches which we aim to explore” comments Charlotte
Edenius, Medivir’s EVP of Research and Development

The transaction value, which consists of up-front payment as well as future
potential milestone payments, is not disclosed.

For more information about Medivir, please contact:

Medivir                      Direct: +46 8 440 6550 or:
Rein Piir, EVP Corporate     Mobile: +46 708 537 292
Affairs & IR
M:Communications             medivir@mcomgroup.com
Europe: Mary-Jane Elliott,   +44(0)20 7920 2330
Amber Bielecka, Hollie Vile

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir
(TMC435), a novel protease inhibitor in phase III clinical development for
hepatitis C that is being developed in collaboration with Janssen
Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia.
and today Medivir has a broad product portfolio with prescription
pharmaceuticals in the Nordics.

Medivir’s first product, the unique cold sore product Xerese®/Xerclear®, is
launched in collaboration with GlaxoSmithKline to be sold OTC under the brand
name ZoviDuo in Europe, Japan and Russia.

Medivir’s IPO was in 1996 and currently the company has around 180 employees.

For more information about Medivir, please visit the Company’s website:
www.medivir.com